ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2158

Evaluating Nailfold Capillary Changes as Indicators of Disease Activity in Juvenile Dermatomyositis

Zilan Zheng1, Laila Metni2, Susan Kim3 and Jessica Neely4, 1University of California, San Francisco, San Francisco, CA, 2University of California, Berkeley, Berkeley, CA, 3UCSF Benioff Children's Hospital, San Francisco, CA, 4UCSF, San Francisco, CA

Meeting: ACR Convergence 2025

Keywords: dermatomyositis, Disease Activity, Imaging, Pediatric rheumatology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2124–2158) Pediatric Rheumatology – Clinical Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Juvenile dermatomyositis (JDM) is a rare pediatric autoimmune myopathy characterized by skin and muscle inflammation, resulting in microvascular changes that can be visualized in the nailfold capillaries. Nailfold video capillaroscopy (NVC) at 200x magnification is a promising non-invasive measure to study disease activity. Here, we studied the association of nailfold capillary measurements with disease activity and compared rheumatologists’ examination (RE) at 10x magnification to NVC.

Methods: Patients diagnosed with JDM at a single tertiary care pediatric rheumatology center had nailfold capillaries imaged during clinic visits following published protocols. Clinical data (e.g., skin assessments and visual analog scale (VAS) scores) and notes on capillary appearances were extracted from medical records. Two cohorts were defined based on disease activity status at time of imaging: active JDM (physician VAS score > 0.5) and inactive JDM (physician VAS score < 0.5). Automated analysis of the NVC images were completed by Capillary.io, measuring capillary limb widths and apical diameters, followed by manual review for accuracy, apex widths, and internal diameters (Table 2, Fig 1). Each capillary characteristic was averaged per patient before analysis. Fisher and Wilcoxon rank sum tests were applied for categorical and continuous variables respectively. Data was stratified by RE at 10x: normal, mild-minimal, and abnormal. One-way ANOVA on ranks was applied, to assess for differences across the groups (P-value < 0.01). NVC measurements were compared to a published study of healthy pediatric capillaries.

Results: 29 JDM patients (mean age 11.79 ± 5.81) had 169 images analyzed, divided into 2 groups of 14 active and 15 inactive patients. Analysis of clinical variables between the two cohorts revealed active JDM exhibited more active skin disease and presence of periungual capillary loop change, active calcinosis, malar erythema, and chronic muscle weakness (Table 1). Active JDM was associated with decreased capillary density and enlarged arterial limb widths, apex widths, and internal diameters on NVC (Table 2, Fig 1). There was no significant difference in abnormal morphology between the two groups, but inactive JDM had significantly more normal capillaries per millimeter (Table 2). Between 80% to 100% of inactive JDM had NVC measurements within normal ranges, compared to about half of those with active JDM. Analysis of RE revealed patients described as “normal” on 10x met 4-5 of the normal 200x ranges, while “abnormal” met none.

Conclusion: Abnormal capillaries observed at 10x and 200x magnification were associated with active skin disease and muscle weakness in JDM, suggesting that nailfold capillaries, specifically arterial limb and apex widths, may serve as a clinical biomarker of disease activity. In addition, NVC showed abnormal measures could be detected and quantified in patients described clinically as “abnormal” or “mild-minimal” changes. Determining the clinical utility added by NVC will be an important area of future study along with identifying features that can help predict future flares, remission, and guide medications tapering.

Supporting image 1Table 1. Demographics & Disease Activity of Patients with Juvenile Dermatomyositis (JDM) with Nailfold Capillary imaging

Supporting image 2Table 2. Analysis of capillaries

Supporting image 3Figure 1. “Active” versus “Inactive” JDM Capillaries


Disclosures: Z. Zheng: None; L. Metni: None; S. Kim: Cabaletta, 1; J. Neely: None.

To cite this abstract in AMA style:

Zheng Z, Metni L, Kim S, Neely J. Evaluating Nailfold Capillary Changes as Indicators of Disease Activity in Juvenile Dermatomyositis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/evaluating-nailfold-capillary-changes-as-indicators-of-disease-activity-in-juvenile-dermatomyositis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluating-nailfold-capillary-changes-as-indicators-of-disease-activity-in-juvenile-dermatomyositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology